[go: up one dir, main page]

NO20074666L - Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer - Google Patents

Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer

Info

Publication number
NO20074666L
NO20074666L NO20074666A NO20074666A NO20074666L NO 20074666 L NO20074666 L NO 20074666L NO 20074666 A NO20074666 A NO 20074666A NO 20074666 A NO20074666 A NO 20074666A NO 20074666 L NO20074666 L NO 20074666L
Authority
NO
Norway
Prior art keywords
vegf
inhibitors
imidazo
pyridine compounds
compounds
Prior art date
Application number
NO20074666A
Other languages
English (en)
Inventor
Yvonne Yee Mai Yip
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20074666L publication Critical patent/NO20074666L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer forbindelser som er inhibitorer av VEGF-R2 med formel (I) og fremgangsmåter for anvendelse av disse forbindelsene.
NO20074666A 2005-02-24 2007-09-13 Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer NO20074666L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (1)

Publication Number Publication Date
NO20074666L true NO20074666L (no) 2007-11-09

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074666A NO20074666L (no) 2005-02-24 2007-09-13 Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer

Country Status (34)

Country Link
US (1) US7666879B2 (no)
EP (1) EP1904494B1 (no)
JP (1) JP5055136B2 (no)
KR (1) KR100904938B1 (no)
CN (1) CN101128461B (no)
AR (1) AR056186A1 (no)
AT (1) ATE490254T1 (no)
AU (1) AU2006216710B2 (no)
BR (1) BRPI0609047A2 (no)
CA (1) CA2599124C (no)
CR (1) CR9331A (no)
CY (1) CY1111154T1 (no)
DE (1) DE602006018615D1 (no)
DK (1) DK1904494T3 (no)
DO (1) DOP2006000051A (no)
EA (1) EA011691B1 (no)
ES (1) ES2354716T3 (no)
HK (1) HK1118284A1 (no)
HR (1) HRP20100677T1 (no)
IL (1) IL184717A (no)
MA (1) MA29433B1 (no)
MX (1) MX2007010326A (no)
NO (1) NO20074666L (no)
NZ (2) NZ584753A (no)
PE (1) PE20061098A1 (no)
PL (1) PL1904494T3 (no)
PT (1) PT1904494E (no)
RS (1) RS51590B (no)
SI (1) SI1904494T1 (no)
TN (1) TNSN07323A1 (no)
TW (1) TW200640924A (no)
UA (1) UA91535C2 (no)
WO (1) WO2006091671A1 (no)
ZA (1) ZA200707136B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114941B1 (en) * 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672213C (en) * 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
AU2008313773B2 (en) 2007-10-17 2012-04-12 Novartis Ag Imidazo [1, 2-A] pyridine derivatives useful as ALK inhibitors
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CA2886187C (en) * 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CN104822679B (zh) * 2012-11-29 2016-10-19 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN106029660B (zh) 2013-12-16 2019-11-15 阿萨纳生物科技有限责任公司 P2x3和/或p2x2/3化合物和方法
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
WO2015187818A1 (en) * 2014-06-03 2015-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
CA2952083C (en) 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3344039A4 (en) 2015-09-03 2019-08-28 Arizona Board of Regents on behalf of the University of Arizona LOW MOLECULAR DYRK1A INHIBITORS AND USES THEREOF
CA3017972C (en) * 2016-03-16 2023-03-28 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
WO2020160074A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
US20220098204A1 (en) * 2019-02-18 2022-03-31 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
MX2022000099A (es) * 2019-06-25 2022-04-27 Sinopsee Therapeutics Compuestos para el tratamiento del cancer.
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1200411B1 (en) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6916814B2 (en) 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
WO2003092595A2 (en) 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
WO2004052286A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体

Also Published As

Publication number Publication date
ZA200707136B (en) 2008-11-26
CN101128461B (zh) 2010-12-22
CA2599124A1 (en) 2006-08-31
UA91535C2 (en) 2010-08-10
NZ584753A (en) 2011-06-30
PL1904494T3 (pl) 2011-04-29
NZ560402A (en) 2010-06-25
ATE490254T1 (de) 2010-12-15
DK1904494T3 (da) 2011-02-21
RS51590B (en) 2011-08-31
JP2008531574A (ja) 2008-08-14
SI1904494T1 (sl) 2011-02-28
WO2006091671A1 (en) 2006-08-31
MX2007010326A (es) 2007-10-16
EP1904494A1 (en) 2008-04-02
DE602006018615D1 (de) 2011-01-13
EA200701802A1 (ru) 2008-02-28
HRP20100677T1 (hr) 2011-01-31
AU2006216710B2 (en) 2011-08-11
IL184717A0 (en) 2007-12-03
EP1904494B1 (en) 2010-12-01
JP5055136B2 (ja) 2012-10-24
CN101128461A (zh) 2008-02-20
KR20070099029A (ko) 2007-10-08
CA2599124C (en) 2013-08-06
TW200640924A (en) 2006-12-01
TNSN07323A1 (en) 2008-12-31
US20090227622A1 (en) 2009-09-10
PE20061098A1 (es) 2006-10-20
AR056186A1 (es) 2007-09-26
CY1111154T1 (el) 2015-06-11
HK1118284A1 (en) 2009-02-06
MA29433B1 (fr) 2008-05-02
EA011691B1 (ru) 2009-04-28
KR100904938B1 (ko) 2009-06-29
DOP2006000051A (es) 2006-08-31
IL184717A (en) 2011-11-30
US7666879B2 (en) 2010-02-23
CR9331A (es) 2008-03-31
AU2006216710A1 (en) 2006-08-31
BRPI0609047A2 (pt) 2010-11-16
ES2354716T3 (es) 2011-03-17
PT1904494E (pt) 2010-12-23

Similar Documents

Publication Publication Date Title
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
NO20066055L (no) Pyridinderivater
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20082598L (no) ERBB-inhibitorer
NO20070731L (no) Heterocykliske forbindelser.
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
MX2008001538A (es) Aril piridinas y metodos para su uso.
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
NO20063220L (no) Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
WO2007000337A8 (en) Bicyclic derivatives as p38 kinase inhibitors
NO20082105L (no) Pyrazoloisokinolinderivater
NO20061343L (no) Imidazo[4,5-b]pyridinderivater som induserbare NO-syntaseinhibitorer
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application